Select a community
Fibromyalgia And Chronic Fatigue Syndrome
Find out more about the PatientsLikeMe
Fibromyalgia And Chronic Fatigue Syndrome Community
Home > Community Treatment Reports > Rozerem Treatment Report
What is Rozerem?

Rozerem is a brand name for the drug Ramelton, a melatoninergic prescription sleep aid used in the treatment of insomnia. Read more...Click to read more below

Takeda Pharmaceuticals's Rozerem site

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Insomnia 9 1
Other 1 1

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
1 50%
None
1 50%

Most commonly reported side effects

can't get to sleep
1 50%
Vivid dreams
1 50%
feeling drugged
1 50%
Drowsiness
1 50%
  • Mild
  • Moderate
  • Severe

Dosages

  8mg as needed 2 mg daily 8 mg daily
  2 Number of Patients: 2 1 Number of Patients: 1 5 Number of Patients: 5  

Stop Reasons

Why Patients Stopped Taking Rozerem (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other
2 50% Other: 50%
Did not seem to work
1 25% Did not seem to work: 25%
Course of treatment ended
1 25% Course of treatment ended: 25%

See all 3 patients who’ve stopped taking Rozerem

Duration See details about how long patients take this treatment ▼

Currently Taking Rozerem

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
2
2
1
2

Stopped Taking Rozerem

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
0
1
1
0
0

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
1 50%
Usually
0 0%
Sometimes
1 50%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
1 50%
Not at all
1 50%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 50%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 22, 2009.